Skip to content

Menu

LexBlog, Inc. logo
NetworkSub-MenuBrowse by SubjectBrowse by PublisherJoin the NetworkGet StartedSubscribeSupportContact
Search
Close

OSHA Clarifies Its Position Regarding Post-Incident Drug Testing and Safety Incentive Programs

By Christina Niro on October 23, 2018
Email this postTweet this postLike this postShare this post on LinkedIn

On October 11, 2018, the Occupational Health and Safety Administration (OSHA) issued a memorandum clarifying its position regarding safety incentive programs and post-incident drug testing.

Two years ago, in October 2016, OSHA issued a memorandum that prohibited drug testing employees who reported injuries or illness unless there was an “objectively reasonable basis” for doing so. The rationale was that blanket post-accident drug and alcohol testing violated OSHA’s anti-retaliation provisions. OSHA’s prior guidance also implied that safety incentive programs were unlawful and could create a chilling effect and deter employees from reporting work-related injuries and illnesses.

With respect to post-incident drug testing, OSHA’s most recent memorandum clarifies that “most instances of workplace drug testing are permissible.” The memo specifically includes the following as types of drug testing policies that are not violative of OSHA’s anti-retaliation provisions:

  • Random drug testing
  • Drug testing unrelated to the reporting of a work-related injury or illness;
  • Drug testing under a state workers’ compensation law;
  • Drug testing under other federal law, such as a U.S. Department of Transportation rule; and
  • Drug testing to evaluate the root cause of a workplace incident that caused injury or could have caused injury to employees. In this circumstance, employers must test all the employees whose conduct could have contributed to the incident, not just employees who made reports.

With respect to safety incentive programs, OSHA’s recent memorandum acknowledges that many safety programs do, in fact, promote workplace safety and health, including rate-based safety incentive programs focused on reducing the number of work-related injuries and illnesses as well as programs rewarding employees for reporting near-misses or workplace hazards. OSHA now takes the position that safety incentive programs are only retaliatory and unlawful if they seek to “penalize an employee for reporting a work-related injury or illness rather than for the legitimate purpose of promoting workplace safety and health.”

Employers should regularly review and update their safety incentive programs and drug testing policies to ensure compliance with the new OSHA guidance and business objectives, but now can be much more comfortable that legitimate safety incentive programs and post-accident drug testing policies will not result in citations.

Photo of Christina Niro Christina Niro

Christina advises and represents employers in a broad range of employment law matters, from discrimination, retaliation, and harassment, to cases involving contract disputes, restrictive covenants, trade secret misappropriation and unfair competition. She has litigated and tried cases in state and federal courts and…

Christina advises and represents employers in a broad range of employment law matters, from discrimination, retaliation, and harassment, to cases involving contract disputes, restrictive covenants, trade secret misappropriation and unfair competition. She has litigated and tried cases in state and federal courts and various administrative agencies. Christina also provides employers of all sizes with day-to-day preventive counseling on wage and hour issues, employee discipline, litigation prevention strategies, employee handbook and policy development, and adherence to federal and state family and medical leave laws. Christina also conducts EEO training to help employers understand, prevent and correct discrimination in the workplace.

Read more about Christina NiroEmail
Show more Show less
  • Posted in:
    Employment & Labor
  • Blog:
    Labor & Employment Law Navigator
  • Organization:
    Frantz Ward LLP
  • Article: View Original Source

Call us at 1-800-913-0988 or email sales@lexblog.com.

Facebook LinkedIn Twitter RSS
The Library at LexBlog
  • About LexBlog
  • The Field We Built
  • Library at LexBlog
  • Our Beliefs
  • Our Team
  • Contact LexBlog
  • Disclaimer
  • Editorial Policy
  • Terms of Service
  • Get Started
  • Publishing Solutions
  • Compass
  • Submit a Request
  • Support Center
  • System Status
Copyright © 2026, LexBlog, Inc. All Rights Reserved.
Law blog design & platform by LexBlog LexBlog Logo